Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice
Authors:
- Munehiro TomikawaMTMunehiro Tomikawa
- Toshiro NakayasuTNToshiro Nakayasu
- Katsuhiko TawaraKTKatsuhiko Tawara
- Yasushi AbikoYAYasushi Abiko
- 1 October 1981
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 40 (2) , 101-113
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemiaAtherosclerosis, 1980
- Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-IIAtherosclerosis, 1980
- Probucol in hypercholesterolemia *1A double blind studyAtherosclerosis, 1980
- Clofibrate therapy and gallstone inductionDigestive Diseases and Sciences, 1978
- Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemiaArchives of internal medicine (1960), 1977
- THE TROMSØHEART-STUDYThe Lancet, 1977
- Toxicity of [4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol)], probucol, in mice, rats, dogs and monkeys: Demonstration of a species-specific phenomenonToxicology and Applied Pharmacology, 1973
- The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterolAtherosclerosis, 1973
- The effect of [4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjectsMetabolism, 1969
- A colorimetric method for estimating serum triglyceridesClinica Chimica Acta, 1968